Loading…
Gyre Therapeutics, Inc. is projected to rise to $6.64 by 2027, a +2% move from its current price of $6.52. GYRE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.31 | $6.52 | $6.74 | +0.03% |
| Jul 14 | $6.23 | $6.52 | $6.83 | +0.06% |
| Jul 15 | $6.16 | $6.53 | $6.91 | +0.09% |
| Jul 16 | $6.11 | $6.53 | $6.97 | +0.11% |
| Jul 17 | $6.07 | $6.53 | $7.03 | +0.14% |
| Jul 18 | $6.03 | $6.53 | $7.08 | +0.17% |
| Jul 19 | $5.99 | $6.53 | $7.13 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.99 | $6.53 | $7.13 | +0.20% |
| Week 2 | $5.79 | $6.55 | $7.40 | +0.40% |
| Week 3 | $5.64 | $6.56 | $7.62 | +0.60% |
| Week 4 | $5.52 | $6.57 | $7.82 | +0.80% |
| Week 5 | $5.42 | $6.59 | $8.00 | +1.00% |
| Week 6 | $5.33 | $6.60 | $8.16 | +1.20% |
| Week 7 | $5.25 | $6.61 | $8.32 | +1.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs with anti-inflammatory and anti-fibrotic properties that target organ fibrosis. Its portfolio includes ETUARY (Pirfenidone), an anti-fibrotic drug approved for idiopathic pulmonary fibrosis, and F351 (Hydronidone) in Phase 3 trials for chronic hepatitis B-associated liver fibrosis.
The company also has F573 in Phase 2 for acute/acute-on-chronic liver failure and preclinical programs F230 and F528. Gyre Therapeutics was founded in 2002 and is headquartered in San Diego, California, operating as a subsidiary of GNI USA, Inc. The description presents these programs and corporate details as the core profile of the entity within the healthcare sector.
Gyre Therapeutics, Inc. trades with the symbol GYRE. The current price is $6.52 per share, and the market capitalization is $726.91M, with a rank of 2758. The 30-day forecast points to a path of gradual, long-term growth, moving from the current level toward higher prices in the years ahead.
The long-range view shows an implied max near $58.97 and an avg around $29.67 by 2050, with a 355.1% ROI in that year range.
In the nearer years, the forecast indicates a neutral stance with the 2026–2029 window showing modest upside and neutral sentiment, before a bullish tilt emerges in the 2030s. The 2030 forecast highlights an avg price of $8.79 with a 34.8% ROI, followed by continued upside through 2040 and 2050, where the avg prices and ROI rise to higher levels.
A major floor 28.0% below — a decisive break under it would weaken the trend.
The nearest floor, 14.7% below — buyers have tended to step in here.
The nearest ceiling, 12.6% above — a clean break opens room to run.
A major ceiling 27.8% above — clearing it would confirm fresh momentum.
Key GYRE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GYRE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.90 | Sell | $6.77 | Sell |
| MA 10 | $6.77 | Sell | $6.72 | Sell |
| MA 20 | $6.43 | Buy | $6.57 | Sell |
| MA 50 | $6.54 | Sell | $6.63 | Sell |
| MA 100 | $7.11 | Sell | $6.93 | Sell |
| MA 200 | $7.41 | Sell | $7.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.65 | Neutral |
| Stoch RSI (14) | 11.58 | Buy |
| CCI (20) | 16.22 | Neutral |
| Williams %R (14) | -67.77 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 6.36 | Buy |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 32.23 | Neutral |
| TRIX (15) | 0.20 | Buy |
| Awesome (5,34) | 0.66 | Buy |
| Ultimate (7,14,28) | 51.06 | Neutral |
| Momentum (10) | 0.29 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 6.82 | Sell |
| ADX (14) | 15.00 | Neutral |
| ATR (14) | 0.19 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 50, and the stock’s movement is hovering around the short-term averages with the SMA50 at $6.54 and the SMA200 at $7.41.
The 30-day price action has traded within a range of $5.25 to $8.09, offering a visible boundary for near-term traders. Support is identified at $5.56 and resistance at $7.34, providing potential turning points in the near term. Annualized volatility stands at 60%, underscoring substantial price motion potential despite the neutral sentiment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.56 | $6.52 | $8.70 | 0% | Neutral | |
| $5.19 | $6.64 | $9.06 | +2% | Neutral | |
| $5.68 | $7.52 | $10.71 | +15% | Neutral | |
| $5.63 | $7.67 | $11.29 | +18% | Neutral | |
| $6.29 | $8.79 | $13.31 | +35% | Bullish | |
| $7.59 | $10.87 | $16.86 | +67% | Bullish | |
| $7.76 | $11.34 | $17.98 | +74% | Bullish | |
| $7.70 | $11.49 | $18.58 | +76% | Bullish | |
| $7.49 | $11.40 | $18.77 | +75% | Bullish | |
| $7.50 | $11.63 | $19.47 | +78% | Bullish | |
| $10.72 | $18.12 | $32.55 | +178% | Bullish | |
| $15.08 | $29.69 | $59.00 | +355% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.56 | $6.52 | $7.96 | +0.00% |
| August 2026 | $5.77 | $6.84 | $8.37 | +4.97% |
| September 2026 | $5.59 | $6.69 | $8.29 | -2.23% |
| October 2026 | $5.42 | $6.53 | $8.18 | -2.37% |
| November 2026 | $5.54 | $6.72 | $8.49 | +2.83% |
| December 2026 | $5.59 | $6.82 | $8.70 | +1.57% |
Click any year to see its month-by-month GYRE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Gyre Therapeutics, Inc.'s 2026 outlook centres on $6.52, within a $5.56 to $8.70 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, GYRE could reach as high as $9.06, with a base case around $6.64 and support toward $5.19 — roughly +2% from $6.52. A consolidation phase looks the most probable path here.
Expect GYRE to range from $5.68 to $10.71 through 2028. The $7.52 average target implies a +15% move from current prices. That is up +13% on the projected 2027 average. Price action looks broadly range-bound.
The GYRE price prediction for 2029 points to an average of $7.67 (low $5.63, high $11.29) — a potential gain of +18% on today's $6.52. A consolidation phase looks the most probable path here.
In 2030, GYRE is projected to trade between $6.29 and $13.31, averaging $8.79 — a potential gain of +35% from today's $6.52. That is up +15% on the projected 2029 average. Momentum favours further upside here.
Gyre Therapeutics, Inc.'s 2031 outlook centres on $10.87, within a $7.59 to $16.86 range. That is up +24% on the projected 2030 average. That marks a +67% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, GYRE could reach as high as $17.98, with a base case around $11.34 and support toward $7.76 — roughly +74% from $6.52. Momentum favours further upside here.
Expect GYRE to range from $7.70 to $18.58 through 2033. The $11.49 average target implies a +76% move from current prices. That is up +1% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The GYRE price prediction for 2034 points to an average of $11.40 (low $7.49, high $18.77) — a potential gain of +75% on today's $6.52. Momentum favours further upside here.
In 2035, GYRE is projected to trade between $7.50 and $19.47, averaging $11.63 — a potential gain of +78% from today's $6.52. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Gyre Therapeutics, Inc.'s 2040 outlook centres on $18.12, within a $10.72 to $32.55 range. That is up +56% on the projected 2035 average. That marks a +178% change versus current levels. Momentum favours further upside here.
By 2050, GYRE could reach as high as $59.00, with a base case around $29.69 and support toward $15.08 — roughly +355% from $6.52. Buyers look set to stay in control over this stretch.
Investing $1,000 in GYRE today (≈ 153.374233 GYRE) could be worth
$4,553.1
+$3,553.1 (+355%) by 2050 · US Dollar
Based on the average projected GYRE price of $29.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GYREwould be worth at today's price.
$1,000 invested in GYRE on Jul 10, 2025 (≈ 128.040974 GYRE) would be worth
$834.83
-$165.17 (-16.5%) today · 0.83× · US Dollar
Based on a GYRE entry price of $7.81 vs. today's $6.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.34 | $888.28 | -11.2% |
| 1 month ago | $5.95 | $1,095.8 | +9.6% |
| 3 months ago | $7.39 | $882.27 | -11.8% |
| 6 months ago | $7.7 | $846.75 | -15.3% |
| 1 year ago | $7.81 | $834.83 | -16.5% |
| All time (5.0y) ago | $69 | $94.49 | -90.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GYRE forecast.
Our base-case forecast reaches $13.00 around 2040.
Implied market cap at $13.00: $1.45B
The multi-year forecast paints a bullish trajectory starting in 2030, with an avg price of $8.79 and a ROI of 34.8%. By 2040, the avg price lifts to $18.14 and the ROI to 178.3%, and by 2050 the avg price reaches $29.67 with a ROI of 355.1%. The near-term years (2026–2029) remain neutral, with the avg price moving from $6.52 in 2026 toward higher levels in the following years and a gradual shift toward the bullish outlook.
The forecasted path shows meaningful upside into the 2030s and beyond, but it also carries notable volatility, reflected by an annualized volatility of 60%. These projections are estimates of price levels and returns, not guarantees, and should be considered in the context of the asset’s broader risk profile and market conditions.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $8.79, with a min of $6.29 and a max of $13.30, and a ROI of 34.8%.
The long-range forecast shows a bullish path from 2030 onward with an average price of $8.79 in 2030 rising to $29.67 by 2050 and a 355.1% ROI in 2050, though near-term years are neutral.
Yes. The forecast shows 2031 with an average price of $10.89 and 2032 with $11.33, indicating the potential to exceed $10 in the early 2030s.
The current price is $6.52 per share and the market capitalization is $726.91M.
The 30-day range is $5.25 to $8.09.
Gyre Therapeutics, Inc. Community Discussion
0Share your Gyre Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.